You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 中生製藥(1177.HK)續漲超7% 首季業績超預期
格隆匯 06-01 11:08
格隆匯6月1日丨上週五(29日)收漲7.39%的中生製藥(1177.HK)今日續漲,現報13.1港元,漲7.38%,暫成交6.1億港元,最新總市值1648億港元。中生製藥28日晚間公佈一季度業績稱,期內集團錄得收入約62.22億元(人民幣,下同),同比增長約0.2%;歸屬於母公司持有者應占盈利約8.62億元,同比增長約0.6%;每股盈利約6.85分,擬派發季度股息每股2港仙。績後瑞信發研報指,考慮到公共衞生事件的影響,認為其首季業績優於該行預期。分別上調其2020至2022年每股盈利預期2.68%、2.7%及5.29%,以反映其腫瘤藥物的增長快過預期。將目標價調高20%至13.2港元,評級升至“跑贏大市”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account